Fullerenol Nanoparticles Decrease Blood-Brain Barrier Interruption and Brain Edema during Cerebral Ischemia-Reperfusion Injury Probably by Reduction of Interleukin-6 and Matrix Metalloproteinase-9 Transcription

J Stroke Cerebrovasc Dis. 2018 Nov;27(11):3053-3065. doi: 10.1016/j.jstrokecerebrovasdis.2018.06.042. Epub 2018 Aug 7.

Abstract

Background: The present study aimed to examine the protective role of fullerenol nanoparticles against blood-brain barrier (BBB) interruption and brain edema during cerebral ischemia-reperfusion injury probably by reduction of interleukin-6 (IL-6) and matrix metalloproteinase-9 (MMP-9) transcription.

Methods: The male Wistar rats (weighting 280-320 g) were randomly assigned into four groups as follows: sham, control ischemic, pretreated ischemic, and posttreated ischemic groups. Cerebral ischemia-reperfusion (IR) injury was performed by occlusion of middle cerebral artery (MCA) for 90 minutes followed by twenty-four hours reperfusion. Rats were administered fullerenol 5mg/kg, intraperitoneally, 30 minutes before induction of IR in pretreated ischemic group and immediately after termination of MCA occlusion in posttreated ischemic group. After twenty-four hours reperfusion, the method of Evans blue dye extravasation (EBE) and RT-PCR were used for determination of BBB permeability and mRNA expression levels of MMP-9 and IL-6, respectively. Neuronal deficit score (NDS) and edema of the ischemic hemispheres were also evaluated.

Results: MCA occlusion increased NDS in control ischemic rats (3.16 ± 0.16) with concomitant increase in EBE (15.30 ± 3.98µg/g) and edema (3.53 ± 0.50%). Fullerenol in both pretreated and posttreated ischemic groups reduced NDS (36% and 68%, respectively), EBE (89% and 91%, respectively) and edema (53% and 81%, respectively). Although MCA occlusion increased the mRNA expression levels of MMP-9 and IL-6 in ischemic hemispheres, fullerenol in both treatment groups noticeably decreased the mRNA expression levels of these genes.

Conclusion: In conclusion, fullerenol nanoparticles can protect BBB integrity and attenuate brain edema after cerebral ischemia-reperfusion injury possibly by reduction of IL-6 and MMP-9 transcription.

Keywords: Blood-brain barrier; Fullerenol; Interleukin-6; Ischemic stroke; Matrix metalloproteinase-9.

MeSH terms

  • Animals
  • Blood-Brain Barrier / drug effects*
  • Blood-Brain Barrier / enzymology
  • Blood-Brain Barrier / pathology
  • Brain Edema / enzymology
  • Brain Edema / genetics
  • Brain Edema / pathology
  • Brain Edema / prevention & control*
  • Capillary Permeability / drug effects
  • Disease Models, Animal
  • Down-Regulation
  • Fullerenes / pharmacology*
  • Infarction, Middle Cerebral Artery / drug therapy*
  • Infarction, Middle Cerebral Artery / enzymology
  • Infarction, Middle Cerebral Artery / genetics
  • Infarction, Middle Cerebral Artery / pathology
  • Interleukin-6 / genetics
  • Interleukin-6 / metabolism*
  • Male
  • Matrix Metalloproteinase 9 / genetics
  • Matrix Metalloproteinase 9 / metabolism*
  • Nanoparticles*
  • Neuroprotective Agents / pharmacology*
  • Rats, Wistar
  • Reperfusion Injury / enzymology
  • Reperfusion Injury / genetics
  • Reperfusion Injury / pathology
  • Reperfusion Injury / prevention & control*
  • Transcription, Genetic / drug effects*

Substances

  • Fullerenes
  • Il6 protein, rat
  • Interleukin-6
  • Neuroprotective Agents
  • fullerenol
  • Matrix Metalloproteinase 9
  • Mmp9 protein, rat